Wall Street rally shocks markets as 25 stocks post double-digit gains after Trump tariff twist

What drove the April 14 rally across U.S. stocks?

On April 14, 2025, the U.S. stock market staged a strong rebound, driven by renewed investor optimism after President Donald Trump announced a temporary suspension of new tariffs on smartphones, semiconductors, and other Chinese electronics. The policy shift provided relief to tech and import-heavy industries, which had been under pressure for weeks amid escalating trade rhetoric. The announcement, which came late on April 13, spurred a positive pre-market reaction and translated into robust gains across multiple sectors by market close.

The rally was led by companies in the materials, healthcare, biotech, finance, and energy sectors. While macroeconomic headwinds such as inflation persistence, tight credit, and geopolitical tensions still loom, the day’s performance suggested that traders were seeking opportunities in undervalued or oversold equities, particularly those positioned to benefit from easing trade constraints or sector-specific tailwinds.

Which companies led the surge and why did they outperform?

MP Materials Corp. emerged as the day’s top performer, soaring 21.65% to close at $27.59. The rare earth mining and processing firm, which plays a key role in supplying critical minerals for electric vehicles and defense applications, gained traction amid renewed investor interest in domestic sourcing and supply chain resilience. With global rare earth markets vulnerable to geopolitical shifts, particularly between the U.S. and China, MP Materials’ U.S.-centric footprint has become more attractive to institutions seeking strategic exposure to energy transition assets.

P3 Health Partners Inc., a value-based care provider focused on senior healthcare, climbed 18.60% to $8.99. The company’s low valuation and focus on managed Medicare Advantage plans appealed to investors amid broader discussions around healthcare cost containment and demographic shifts in the U.S. population. The rise also came despite the stock being down more than 60% over the past year, indicating a technical rebound likely driven by short covering and bargain hunting.

Argentine financial stocks featured prominently among the top gainers, reflecting bullish sentiment on improving macroeconomic prospects in Argentina. Banco Macro S.A. surged 15.41% to $91.00, while Banco BBVA Argentina S.A. advanced 14.45% to $20.36 and Grupo Financiero Galicia S.A. gained 14.03% to close at $61.43. These movements mirrored global investor optimism on stabilizing exchange rates, inflation control efforts, and improving regional equity sentiment in Latin American banking sectors.

Summit Therapeutics Inc. rose 12.44% to $26.13, continuing its upward trend that has seen the biotech firm’s stock rise over 600% in the past year. The company’s recent licensing deals and late-stage drug trials have positioned it as one of the most closely watched clinical-stage firms in the sector. Similarly, Certara, Inc., a biosimulation and drug development software provider, jumped 11.54% to $14.40, reflecting investor enthusiasm for AI-driven clinical trial optimization technologies.

In Japan-linked equities, TechnoPro Holdings Inc. gained 11.31% to reach $20.03, reflecting interest in international staffing firms as global labor shortages persist, especially in IT and R&D roles.

Argentine energy and infrastructure names also advanced. Transportadora de Gas del Sur S.A. gained 10.63% to $28.09, while Pampa Energía S.A. added 10.52% to reach $76.91. Both companies benefit from high export prices and improving domestic energy reform outlooks in Argentina. Meanwhile, YPF Sociedad Anónima, the country’s largest integrated energy company, climbed 10.32% to $33.13.

Why did healthcare and biotech names feature so prominently among the gainers?

Healthcare remained a critical outperforming sector, partly due to its defensive qualities in an uncertain macroeconomic environment. Viking Therapeutics, Inc. rose 10.58% to $24.57, fueled by momentum surrounding its metabolic and weight-loss drug pipeline, which has drawn comparisons to industry leaders in the GLP-1 space.

ADMA Biologics, Inc. climbed 7.78% to $20.91 on investor interest in its plasma-derived biologics and the company’s commercial expansion efforts. Similarly, TransMedics Group, Inc., which provides advanced organ transplant transport systems, added 7.77% to close at $86.84. The gains followed increased attention to companies supporting healthcare infrastructure innovation.

China-based biopharma firm HUTCHMED (China) Limited rose 8.53% to $14.89, possibly reflecting stabilization in sentiment toward U.S.-listed Chinese companies following a regulatory lull and potential FDA movement on its oncology drug pipeline.

What role did consumer and housing stocks play in the rally?

Consumer and housing-related stocks showed signs of life amid hopes that easing supply chain costs might support margin recovery in 2025. Bath & Body Works, Inc. gained 7.55% to $28.65, extending its recent rebound as the personal care and fragrance retailer focuses on omnichannel growth and SKU rationalization. Meanwhile, Rocket Companies, Inc., a major mortgage originator, rose 7.98% to $12.85 as falling Treasury yields offered temporary relief to interest rate-sensitive businesses.

WaFd, Inc., the holding company for Washington Federal Bank, gained 8.96% to $26.74. The move came as regional banks saw a modest bounce from recent lows amid expectations that the Federal Reserve may delay further tightening due to international trade concerns.

What was the impact on U.S. housing finance entities?

The housing finance segment recorded significant upside. Federal National Mortgage Association (FNMA) gained 7.76% to $6.25, while its preferred share FNMAS rose 7.69% to $11.20. Additionally, Federal Home Loan Mortgage Corporation (FMCC) gained 8.30% to $5.22. These moves were driven by increased volume in agency MBS and optimism that political scrutiny around GSE reform might ease in the near term, especially as housing affordability challenges pressure policymakers to keep mortgage liquidity flowing.

Which other notable stocks posted strong gains and why?

Canadian eye health company Bausch + Lomb Corporation rose 7.46% to $12.25, bolstered by recovery hopes in its surgical and vision care business units. Specialty chemicals producer Hawkins, Inc. rose 7.88% to $123.83, supported by demand in water treatment and food ingredient markets.

Chinese coffee chain Luckin Coffee Inc. posted a 9.79% increase to $30.74, continuing its comeback narrative after financial restructuring and robust sales growth in its domestic market. Latin American beverage giant Embotelladora Andina S.A. advanced 8.25% to $23.63, aided by expectations of sustained consumption growth in the region and improved supply chain logistics.

What does this mean for investors navigating April’s market uncertainty?

While the rally on April 14 was driven by a mix of macro news and stock-specific catalysts, analysts warned that underlying volatility remains elevated. With ongoing uncertainty around trade policy, global inflation, and earnings outlooks, many strategists recommend maintaining a diversified portfolio and watching for further signs of stabilization in global supply chains and interest rate trajectories.

Short-term relief rallies like this one offer opportunities, but also underscore the importance of managing exposure to sectors most sensitive to geopolitical and regulatory swings.